Stock Analysis
Summit Therapeutics Inc. (SMMT) Stock Analysis
Summit Therapeutics Inc. (SMMT) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Summit Therapeutics Inc. (SMMT) currently has an AIQ Score of 47/100, indicating a bearish setup. Momentum is the strongest factor at 65/100. Quality is the weakest current factor at 30/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
SMMT at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $14.15 |
| AIQ Score | 47/100 |
| Overall View | Bearish |
| Technical Analysis Consensus | Strong Sell |
| Market Cap | $11.29B |
| P/E Ratio (TTM) | -13.22 |
| Forward P/E | — |
| EPS (Q3 FY2026) | -$0.26 |
| Revenue (Q3 FY2026) | $0 |
| Dividend Yield (TTM) | 0.00% |
| Beta | 1.89 |
| Volume | 5.56M |
| 52-week range | $12.07-$29.23 |
| RSI 14 | 42.17 |
| 50-Day SMA | $16.41 |
| 200-Day SMA | $16.15 |
| Analyst Price Target | $31.50 |
| Next Earnings | Feb 22, 2027 |
SMMTSummit Therapeutics Inc.
Healthcare / Biotechnology
Relative Leader / Watch
Strong Relative Position
Latest quote
- Momentum65
- Value—
- Quality30
- Risk resilience38
- Sentiment—
SMMT Stock Analysis Summary
Summit Therapeutics Inc. (SMMT) currently has an AIQ Score of 47/100, indicating a bearish setup. Momentum is the strongest factor at 65/100. Quality is the weakest current factor at 30/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bearish regime, SMMT has AIQ Score of 47/100 with Momentum base of 65/100 and fading Quality at 30/100. Wait for component alignment before adding exposure.
Momentum (65/100) leads while Quality (30/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -6.14% stock move · SMMT classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is SMMT Bullish or Bearish Right Now?
SMMT currently has a bearish overall setup. Momentum is the strongest factor at 65/100, while Quality is weakest at 30/100. The current evidence suggests a bearish setup.
- - Momentum is constructive at 65/100.
- - Analyst target implies +122.61% upside from the latest quote.
- - Risk Resilience is weak at 38/100.
- - Price is -12.37% below its 200-day SMA.
- - Technical consensus has more sell votes than buy votes (35 vs 7).
Current Consensus
SMMT's Technical Analysis Consensus is currently Strong Sell, with 7 buy, 4 neutral, and 35 sell votes. SMMT's 14-day RSI is 42.17, which places the stock in a weaker momentum range. SMMT's beta is 1.89, indicating greater market sensitivity than the broad market.
What Changed in SMMT?
The largest recent change in SMMT is Momentum moving up by 3.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the SMMT Outlook?
The current bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
SMMT Decision Framework
Public evidence layers, setup checks, and risk context for Summit Therapeutics Inc..
Summit Therapeutics Inc. (SMMT) Stock Analysis
Summit Therapeutics Inc. has an AIQ Score of 47/100 in a Bearish regime. Momentum is strongest at 65/100. Beta is 1.89, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | SMMT is in a Bearish AIQ regime with score 47/100. |
| Signal Conflict | The primary conflict is that momentum leads at 65/100 while quality lags at 30/100. |
| Factor Evidence | Momentum 65/100 · Quality 30/100 · Risk 38/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 65/100.
Momentum is 65/100 and RSI (14) is 42.2.
SMMT is in a Bearish regime at 47/100.
Risk factor is 38/100 with beta 1.89 and annual volatility 75.92%.
Current conflict: momentum leads at 65/100 while quality lags at 30/100.
SMMT Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
SMMT Fundamentals
SMMT valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
SMMT Technical Analysis
SMMT technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
SMMT Stock Catalysts
Track SMMT earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
SMMT Dividend Analysis
SMMT dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
SMMT Financial Data
SMMT revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
SMMT Risk Analysis
SMMT volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
SMMT Stock News
SMMT stock news, market tone, recent headlines, and catalyst context.
SMMT vs Biotechnology Peers
Current peer cohort: SMMT · SNDX · SRRK · STOK · SYRE. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| SMMT Current stock | 47/100 | — | 65/100 | 38/100 | -0.01 | 75.92% | Current |
| SNDX Syndax Pharmaceuticals, Inc. | 43/100 | 64/100 | 14/100 | 37/100 | -0.76 | 57.16% | SMMT vs SNDX |
| SRRK Scholar Rock Holding Corporation | 39/100 | — | 54/100 | 52/100 | 0.84 | 57.45% | SMMT vs SRRK |
| STOK Stoke Therapeutics, Inc. | 42/100 | 22/100 | 47/100 | 59/100 | 0.23 | 53.19% | SMMT vs STOK |
| SYRE Spyre Therapeutics, Inc. | 64/100 | 44/100 | 81/100 | 53/100 | 2.57 | 66.66% | SMMT vs SYRE |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for SMMT: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching SMMT
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for SMMT
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
SMMT Stock FAQ
What is SMMT stock price today?
Summit Therapeutics Inc.'s current stock price is $14.15. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is SMMT bullish or bearish right now?
SMMT's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is SMMT's market cap?
SMMT's market cap is $11.29B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is SMMT's current P/E ratio?
SMMT's current P/E ratio is -13.22 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is SMMT's RSI?
SMMT's 14-day RSI is 42.17 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is SMMT above its 50-day and 200-day moving averages?
SMMT is -13.78% from its 50-day SMA and -12.37% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is SMMT's next earnings date?
SMMT's next earnings date is currently listed as Feb 22, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does SMMT pay a dividend?
SMMT's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.